Clinical Trials
314 trialsNCT05700448 2026-05-27
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
CStone Pharmaceuticals
Phase 3 Not yet recruiting
NCT07499128 2026-05-27
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
National Institutes of Health Clinical Center (CC)
Phase NA Not yet recruiting
NCT07524530 2026-05-27
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Not yet recruiting
NCT07572136 2026-05-27
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
NCT07607925 2026-05-27
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
GlaxoSmithKline
Phase 1/2 Not yet recruiting
NCT07608549 2026-05-27
FLASH Pilot Phase 1 Safety Study
Dartmouth-Hitchcock Medical Center
Phase NA Not yet recruiting
NCT07609823 2026-05-27
A Phase 2 Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2 Not yet recruiting
NCT07609862 2026-05-27
A Phase Ib/II Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1/2 Not yet recruiting
NCT07478848 2026-05-22
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
Phase 1 Not yet recruiting
NCT07592481 2026-05-22
HEMO-CONNECT
Centre Hospitalier de la côte Basque
Phase NA Not yet recruiting
NCT07601607 2026-05-22
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT07603479 2026-05-22
A Phase I Study of JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Jecho Biopharmaceuticals Co., Ltd.
Phase 1 Not yet recruiting
NCT07551583 2026-05-20
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07387926 2026-05-19
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting
NCT07593482 2026-05-18
FC-BALANCE
Swiss Cancer Institute
Phase 2 Not yet recruiting
NCT07583810 2026-05-15
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07588698 2026-05-15
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
NCT07449832 2026-05-14
SPELH
Rennes University Hospital
Phase NA Not yet recruiting
NCT07451054 2026-05-14
CD45BE-HSPC + CART-45 Cells
University of Pennsylvania
Phase 1 Not yet recruiting
NCT07585747 2026-05-14
CUREMZL002
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07586618 2026-05-14
ALT-101
Allterum Therapeutics, Inc
Phase 1 Not yet recruiting
NCT07101328 2026-05-13
BAF_FRontier-1
Eli Lilly and Company
Phase 1 Not yet recruiting
NCT07332507 2026-05-13
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07444710 2026-05-13
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07517705 2026-05-13
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
University of Nebraska
Phase 2 Not yet recruiting
NCT07573111 2026-05-13
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Laguna Biotherapeutics, Inc.
Phase 1 Not yet recruiting
NCT07583212 2026-05-13
Phase I Study of HRS-1635 in B-cell Malignancies
Chengdu Suncadia Medicine Co., Ltd.
Phase 1 Not yet recruiting
NCT07583771 2026-05-13
A Phase â… Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Chipscreen Biosciences, Ltd.
Phase 1 Not yet recruiting
NCT07584850 2026-05-13
Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ruijin Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT07582159 2026-05-12
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07451197 2026-05-11
Family-Focused Study to Support Medication for Opioid Use Disorder
University of Wisconsin, Madison
Phase NA Not yet recruiting
NCT07578077 2026-05-11
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
Phase 1/2 Not yet recruiting
NCT07444632 2026-05-08
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07575412 2026-05-08
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT07576725 2026-05-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT07572175 2026-05-07
SPARTACUS
Icahn School of Medicine at Mount Sinai
Phase 2 Not yet recruiting
NCT06739447 2026-05-06
Hospital Based Continuous Patient Monitoring System
University of Alabama at Birmingham
Phase NA Not yet recruiting
NCT07164469 2026-05-06
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07301424 2026-05-06
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
University of Alberta
Phase 2 Not yet recruiting
NCT07569965 2026-05-06
FRONTIER
Miltenyi Biomedicine GmbH
Phase 2 Not yet recruiting
NCT06970496 2026-05-05
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT07178912 2026-05-05
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07192237 2026-05-05
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07283640 2026-05-05
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07555431 2026-05-04
DOT-H
Fundação Bahiana de Infectologia
Phase 2 Not yet recruiting
NCT07563543 2026-05-04
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1 Not yet recruiting
NCT07565220 2026-05-04
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
University of Pittsburgh
Phase 1 Not yet recruiting
NCT05728879 2026-05-01
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Northwestern University
Phase EARLY_PHASE1 Not yet recruiting
NCT06594939 2026-05-01
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
Medical College of Wisconsin
Phase 2 Not yet recruiting
NCT07562022 2026-05-01
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Sinocelltech Ltd.
Phase 3 Not yet recruiting